Cytotoxic and anti-inflammatory active methylsulfanyltriazoloquinazolines

Journal of Pure and Applied Microbiology

Volumn 7, Issue SPEC. ISS. NOVEMB, 2013, Pages 189-198

  Al Salahi, Rashad A ^a   Gamal Eldeen, Amira M ^b   Alanazi, Amer M ^a   Al Omar, Mohamed A ^a   Marzouk, Mohamed A ^a,b   Fouda, Moustafa M G ^b,c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b NATIONAL RESEARCH CENTRE   (Egypt)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

1,2,4 Triazoloquinazoline; Antitumor; HCT 116; Hep G2; Inflammation

Indexed keywords

2 METHYLSULFANYL 3 PYRIDYL BIS [1,2,4]TRIAZOLO[1,5 A:4,3 C]QUINAZOLINE; 2 METHYLSULFANYL 5 ETHOXY [1,2,4]TRIAZOLO [1,5 A]QUINAZOLINE; 2 METHYLSULFANYL [1,2.4]TRIAZOLO[1,5 A]QUINAZOLINE DERIVATIVE; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BACTERIUM LIPOPOLYSACCHARIDE; CYTOTOXIC AGENT; NITRIC OXIDE; PACLITAXEL; PROSTAGLANDIN E2; QUINAZOLINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL STRAIN HEPG2; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MACROPHAGE; NONHUMAN;

EID: 84893055449     PISSN: 09737510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Lu, H., Ouyang, W., Huang, C. Inflammation, a Key Event in Cancer Development. Mol. Cancer Res., 2006;4:221-43.
2. a. Levy, B.D., Clish, C.B., Schmidt, B., Gronert, K., Serhan, C.N. Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol., 2001;2:612-19
3. b. Rastegar, H., Mirzaei, A., Ashtiani, H. R. A., Hedayati, M., Ahmadi, S. The Effect of Extracted Bacterial Salmonella enteritidis Lipopolysaccharide on Inducible Nitric Oxide Synthase in Human Liver Hepatocellular Carcinoma Cell Lines in Induction and Inhibition Conditions. J. pure Appl. Microbiol., 2012;6:39-45.
4. Hodge-Dufour, J., Marino, M.W., Horton, M.R. Inhibition of interferon gamma induced interleukin 12 production: A potential mechanism for the anti-inflammatory activities of tumor necrosis factor. Proc. Natl. Acad. Sci.USA, 1998;95:13806-11.
5. Nathan, C. Points of control in inflammation. Nature, 2002;420:846-52.
6. Savill, J, Wyllie, A.H., Henson, J.E., Walport, M.J., Henson, RM., Haslett, C. Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin. Invest., 1989;83:865-75.
7. Savill, J., Fadok, V.A. Corpse clearance defines the meaning of cell death. Nature, 2000;407:784-8.
8. Savill, J., Dransfield, I., Gregory, C, Haslett, C. A blast from the past: Clearance of apoptotic cells regulates immune responses. Nat. Rev. Immunol., 2002;2:965-75.
9. Fadok, V. A., Bratton, D.L., Konowal, A., Freed, P.W., Westcott, J. Y., Henson, P.M. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J. Clin. Invest., 1998;101:890-8.
10. McDonald, P.P., Fadok, V.A., Bratton, D., Henson, P.M. Transcriptional and translational regulation of inflammatory mediator production by endogenous TGF-beta in macrophages that have ingested apoptotic cells. J. Immunol., 1999;163:6164-72.
11. Huynh, M. L. N., Fadok, V.A., Henson, P.M. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-betal secretion and the resolution of inflammation. J. Clin. Invest., 2002;109:41-50.
12. Philip, M., Rowley, D.A., Schreiber, H. Inflammation as a tumor promoter in cancer induction, Semin. Cancer Biol., 2004;14:433-9.
13. Coussens, L.M., Werb, Z. Inflammation and cancer. Nature, 2002;420:860-7.
14. Macarthur, M., Hold, G.L., El-Omar, E.M. Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. J. Am. Physiol Gast Liver Physiol., 2004;286: G515-G20.
15. Martin, Y.C., Austel, K.E. (eds.): Paths to Better and Safer Drugs, Modern Drug Research, New York, NY, USA: Marcel Dekker, 1989; pp. 243-73.
16. rd. edn., Stuttgart, Germany: Deutscher Apotheker Verlag, 2000; p. 51.
17. Harris, CR., Thorarensen, A. Advances in the discovery of novel antibacterial agents during the year 2002. Curr. Med. Chem., 2004;11:2213-43.
18. Andries, K., Verhasselt, P., Guillemont, J., Gohlmann, H.W., Neefs, J.M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005;307:223-6.
19. Vangapandu, S., Jain, M., Jain, R., Kaur, S., Singh, P.P. Ring-substituted quinolines as potential anti-tuberculosis agents. Bioorg. Med. Chem., 2004;12:2501-8.
20. Carta, A., Piras, S., Palomba, M, Jabes, D., Molicotti, P., Zanetti, S. Anti-mycobacterial activity of quinolones. Triazoloquinolones a new class of potent anti-mycobacterial agents. Anti Infective Agents Med. Chem., 2008;7:134-47.
21. Padia, J.K., Field, M., Hilton, J;, Meecham, K., Pablo, J., Pinnock, R., Roth, B.D., Singh, L., Suman-Chauhan, N., Trivedi, B.K. Novel nonpeptide CCK-B antagonists: Design and development of quinazolinone derivatives as Potent, Selective, and orally active CCKB Antagonists. J. Med. Chem., 1998;41:1042-9.
22. Xia, Y., Yang, Z.Y., Hour, M.J., Kuo, S.C., Xia, P., Bastow, K.F., Nakanishi, Y, Nampoothiri, P., Hackl, T., Hamel, E. Antitumor agents. Part 204: Synthesis and biological evaluation of substituted 2-aryl quinazolinones. Bioorg. Med. Chem. Lett., 2001;11:1193-6.
23. Kenichi, O., Yoshihisa, Y, Toyonari, O., Toru, I., Yoshio, I. Studies on 4(1H)-quinazolinones. 5. Synthesis and antiinflammatory activity of 4(1H)-quinazolinone derivatives. J. Med. Chem., 1985;28:568-76.
24. Buchanan, J.G., Sable, H.Z. Selective Organic Transformations, Thygarajan B.S., (ed.): New York, NY, USA, Wiley Interscience, 1972; Volume 2, pp. 1-95.
25. Hamidian, H., Tikdari, A.M., Khabazzadeh, H. Synthesis of new 4(3H)-quinazolinone derivatives using 5(4H)-oxazolones. Molecules, 2006;11:377-82.
26. Birendra, N.G., Jiban, C. S. K., Jogendra, N.B. Quinoline-based fused heterocyclic systems are found as potential anticancer. J. Heterocycl. Chem., 1984;21:1225-9.
27. Kothari, P.J., Mehlhoff, M.A., Singh, S.P., Parmar, S.S., Stenberg, V.I. Synthesis of some new 5-methyl-2-benzoxazolinone derivatives and investigation on their analgesic-antiinflammatory Activities. J. Heterocycl. Chem., 1980;17:1369-72.
28. Sengupta, A.K., Misra, H.K. Studies on potential pesticides 13 Synthesis and evaluation of s(3-substituted-phenoxymethyl-4-aryl/cyclohexyl-4h-1,2,4- triazol-5-yl)-2-mercaptomethyl benzimidazoles for antibacterial and insecticidal activities. J. Indian Chem. Soc., 1981;8:508.
29. a. Sarmah, S.C., Bahel, S.C. Synthesis of aryloxy/aryl acetyl thiosemicarbazides, substituted 1,3,4-oxadiazoles, 1,3,4-thiadiazoles, 1,2,4-triazoles and related compounds as potential Fungicides. J. Indian Chem. Soc., 1982;59:877-80.
30. b. Kumar, U., Bansal, M., Gupta, S. K., Saharyar, M. Synthesis and Antifungal Activity of 4-amino-5-aryl-1,2,4-triazoles. J. Pure Appl. Microbiol., 2007;1:341-344.
31. Francis, J.E., Cash, W.D., Psychoyos, S., Ghai, G., Wenk, P., Friedmann, R.C., Atkins, C., Warren, V, Furness, P., Hyun, T.L. Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists. J. Med. Chem., 1988;31:1014-20.
32. Kim, Y.-C., De Zwart, M., Chang, L., Mora, S., Kuenzel, J., Melman, N., Jzerman, A.P., Jacobson, K.A. Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) having high potency at the human A2B and A3 receptor subtypes. J. Med. Chem., 1998;41:2835-45.
33. Ongini, E., Monoppoli, A., Cacciari, B., Baraldi, P.G. Selective adenosine A2A receptor Antagonists. Il Farmaco, 2001;56:87-90.
34. Francis, J.E., Cash, W.D., Barbaz, B.S., Bernard, P.S., Lovell, R.A., Mazzenga, G.G, Friedmann, R.G, Hyun, J.L., Braunwalder, A.F., Loo, P.S. Synthesis and benzodiazepine binding activity of a series of novel [1,2,4]triazolo[1,5-c]quinazolin-5(6H)-ones. J. Med. Chem., 1991;34:281-90.
35. Alagarsamy, V., Giridhar, R., Yadav, M.R. Synthesis and pharmacological investigation of novel 1-substituted-4-phenyl-1,2,4-triazolo [4,3-a]quinazolin-5(4H)-ones as a new class of H1-antihistaminic agents. Bioorg. Med. Chem. Lett., 2005;15:1877-80.
36. Alagarsamy, V., Solomon, V.R., Murugan, M. Synthesis and pharmacological investigation of novel 4-benzyl-1-substituted-4H-[1,2,4]triazolo [4,3-a]quinazolin-5-ones as new class of H1-antihistaminic agents. Bioorg. Med. Chem., 2007;15:4009-15.
37. Al-Salahi, R., Geffken, D., Koellner, M. A new series of 2-Alkoxy(aralkoxy)[1,2,4]triazolo[1,5 a]quinazolin-5-ones as Adenosine Receptor Antagonists. Chem. Pharm. Bull., 2011;59:730-3.
38. Al-Salahi, R., Geffken, D. Synthesis of novel 2-alkoxy(aralkoxy)-4H-[1,2, 4]triazolo[1,5-a]quinazolin-5-ones starting with dialkyl-N-cyanoimidocarbonates. J. Heterocycl Chem., 2011;48:656-62.
39. Al-Salahi, R., Marzouk, M., Awad, G., Al-Omer M., Ezzeldin, E. Antimicrobial activity of a newly synthesized 2-methylsulfanyl-[1,2,4] triazolo[1,5-a]quinazolin-5-one and its derivatives. J. Pharm. Pharmacol., 2013;65:790-7.
40. Al-Salahi R., Geffken, D. Synthesis and reactivity of [1,2,4]triazolo-annelated quinazolines, Molecules, 2010;15:7016-34.
41. Jantova, S., Ovadekova, R., Letasiova, S., Spirkova, K., Stankovsky, S. Anti-microbial activity of some substituted triazolo-quinazolines. Folia Microbiol., 2005;50:90-4.
42. Al-Omary, M.F., Abouzeid, L. A., Nagi, M.N., Habib, E.E., Abdel-Aziz, A. El-Azab, A.S., Abdel-Hamide, S.G., Al-Omar, M.A., Al-Obaid, A.M., El-Subbagh, H.I. Non-classical antifolates. Part 2: Synthesis, Biological evaluation, And molecular modeling study of some new 2,6-substituted-quinazolin-4-ones. Bioorg. Med. Chem., 2010;18:2849-63.
43. Hansen, M.B., Nielsen, S.E., Berg, K. Reexamination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Meth., 1989;119:203-10.
44. Gerhaeuser, C, Elke Heiss, K.K., Neumann, I., Gamal-Eldeen, A., Knauft, J., Liu, G.-Y., Sitthimonchai, S., Fran, N., Mechanism-based in vitro screening of potential cancer chemo-preventive agents. Mutat. Res., 2003;523(4):163-72.
45. Smith, P.K., Krohn, R.I., Hermanson, G.T., Mallia, A.K., Gartner, F.H., Provenzano, M.D., Fujimoto, E.K., Goeke, N.M., Olson, B.J., Klenk, D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem., 1985;150:76-85.
46. Al-Salahi, R., Geffken, D. Synthesis of 2-methylsulfanyl-4H-[1,2,4] triazolo[1,5-a]quinazolin 5-one and derivatives. Synth. Comm., 2011;41:3512-23.
47. Hong, W.K., Sporn, M.B. Recent advances in chemoprevention of cancer. Science, 1997;278:1073-7.
48. Bertram, J.S. The molecular biology of cancer. Mol. Asp. Med., 2000;21:167-223.
49. Aggarwal, B.B., Shishodia, S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol., 2006;71:1397-421.
50. Rooseboom, M., Commandeur, J. N. M., Vermeulen, N. P. E. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol. Rev., 2004;56:53-102.
51. Alper, A.E., Taurine, A. Thiazolo[3,2-a] benzimidazoles. Can. J. Chem., 1967;45:2903-12.
52. Omiecinski, C.J., Hassett, C, Hosagrahara, V. Epoxide hydrolase-polymorphism and role in Toxicology, Toxicol. Lett., 2000;112-113, 365-70.